185 related articles for article (PubMed ID: 24654698)
1. The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.
Kapoor KG; Wagner MG; Wagner AL
Semin Ophthalmol; 2015; 30(5-6):475-81. PubMed ID: 24654698
[TBL] [Abstract][Full Text] [Related]
2. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jacques ML; Jiao J; Li XY; Whitcup SM;
Ophthalmology; 2010 Jun; 117(6):1134-1146.e3. PubMed ID: 20417567
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Chang-Lin JE; Burke JA; Peng Q; Lin T; Orilla WC; Ghosn CR; Zhang KM; Kuppermann BD; Robinson MR; Whitcup SM; Welty DF
Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4605-9. PubMed ID: 21421864
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic and clinical profile of dexamethasone intravitreal implant.
Robinson MR; Whitcup SM
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):629-47. PubMed ID: 23234323
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes.
Bhagat R; Zhang J; Farooq S; Li XY
J Ocul Pharmacol Ther; 2014 Dec; 30(10):854-8. PubMed ID: 25411827
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis.
Bratton ML; He YG; Weakley DR
J AAPOS; 2014 Apr; 18(2):110-3. PubMed ID: 24698604
[TBL] [Abstract][Full Text] [Related]
7. Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera.
Meyer CH; Klein A; Alten F; Liu Z; Stanzel BV; Helb HM; Brinkmann CK
Retina; 2012; 32(10):2133-40. PubMed ID: 23060033
[TBL] [Abstract][Full Text] [Related]
8. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
Chang-Lin JE; Attar M; Acheampong AA; Robinson MR; Whitcup SM; Kuppermann BD; Welty D
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):80-6. PubMed ID: 20702826
[TBL] [Abstract][Full Text] [Related]
10. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.
Zarranz-Ventura J; Carreño E; Johnston RL; Mohammed Q; Ross AH; Barker C; Fonollosa A; Artaraz J; Pelegrin L; Adan A; Lee RW; Dick AD; Sallam A
Am J Ophthalmol; 2014 Dec; 158(6):1136-1145.e5. PubMed ID: 25217856
[TBL] [Abstract][Full Text] [Related]
11. EFFICACY AND SAFETY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR PERSISTENT UVEITIC CYSTOID MACULAR EDEMA.
Khurana RN; Porco TC
Retina; 2015 Aug; 35(8):1640-6. PubMed ID: 25741813
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study).
Capone A; Singer MA; Dodwell DG; Dreyer RF; Oh KT; Roth DB; Walt JG; Scott LC; Hollander DA
Retina; 2014 Feb; 34(2):342-51. PubMed ID: 23846381
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.
Callanan DG; Gupta S; Boyer DS; Ciulla TA; Singer MA; Kuppermann BD; Liu CC; Li XY; Hollander DA; Schiffman RM; Whitcup SM;
Ophthalmology; 2013 Sep; 120(9):1843-51. PubMed ID: 23706947
[TBL] [Abstract][Full Text] [Related]
14. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
Bakri SJ; Omar AF
J Ocul Pharmacol Ther; 2012 Oct; 28(5):547-9. PubMed ID: 22537269
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.
Lowder C; Belfort R; Lightman S; Foster CS; Robinson MR; Schiffman RM; Li XY; Cui H; Whitcup SM;
Arch Ophthalmol; 2011 May; 129(5):545-53. PubMed ID: 21220619
[TBL] [Abstract][Full Text] [Related]
16. Laser-induced intrachoroidal dexamethasone drug delivery system to posterior eye segment.
Murata M; Sanbe A; Lee JW; Nishigori H
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8317-24. PubMed ID: 24265021
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
19. The dexamethasone drug delivery system: indications and evidence.
London NJ; Chiang A; Haller JA
Adv Ther; 2011 May; 28(5):351-66. PubMed ID: 21494891
[TBL] [Abstract][Full Text] [Related]
20. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases.
Agrawal R; Fernandez-Sanz G; Bala S; Addison PK
Br J Ophthalmol; 2014 Jul; 98(7):961-3. PubMed ID: 24648417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
